Literature DB >> 373478

The management of inadvertent subcutaneous adriamycin infiltration.

R A Laughlin, J M Landeen, M B Habal.   

Abstract

Once the inadvertent infiltration of Adriamycin occurs, it is recommended to immediately treat the problem. This has been accomplished by wide excision and meshed split thickness skin grafting for resurfacing of the defect. Obtaining a healed wound alleviates the stiffness from lack of motion or ruptured tendons. Pain from the open ulcer, which is prone to infection in the immunosuppressed patient, is lessened. An analogy between pit viper envenomization and Adriamycin infiltration is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 373478     DOI: 10.1016/0002-9610(79)90077-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

Review 1.  [Antineoplastic drug-induced extravasation].

Authors:  Maike de Wit
Journal:  Med Klin (Munich)       Date:  2010-11

Review 2.  Cancer chemotherapy agent-induced perivenous extravasation injuries.

Authors:  A Banerjee; T M Brotherston; B G Lamberty; R C Campbell
Journal:  Postgrad Med J       Date:  1987-01       Impact factor: 2.401

Review 3.  Why don't we use vitamin E in dermatology?

Authors:  K Pehr; R R Forsey
Journal:  CMAJ       Date:  1993-11-01       Impact factor: 8.262

4.  Amelioration of doxorubicin-induced skin necrosis in mice by butylated hydroxytoluene.

Authors:  J P Daugherty; A Khurana
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Indocyanine green video angiography predicts outcome of extravasation injuries.

Authors:  Werner Haslik; Ursula Pluschnig; Günther G Steger; Christoph C Zielinski; K F Schrögendorfer; Jakob Nedomansky; Rupert Bartsch; Robert M Mader
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

Review 6.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.